Neuberger Berman Group LLC Reduces Stock Holdings in Humana Inc. (NYSE:HUM)

Neuberger Berman Group LLC trimmed its position in Humana Inc. (NYSE:HUM) by 4.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 318,693 shares of the insurance provider’s stock after selling 14,448 shares during the period. Neuberger Berman Group LLC’s holdings in Humana were worth $140,690,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Baillie Gifford & Co. purchased a new position in Humana in the second quarter worth about $26,000. Cordasco Financial Network purchased a new position in shares of Humana during the 2nd quarter valued at about $33,000. Credit Agricole S A purchased a new position in shares of Humana during the 2nd quarter valued at about $46,000. Sandy Spring Bank lifted its position in shares of Humana by 126.6% during the 2nd quarter. Sandy Spring Bank now owns 179 shares of the insurance provider’s stock valued at $79,000 after buying an additional 100 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its position in shares of Humana by 14.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 192 shares of the insurance provider’s stock valued at $85,000 after buying an additional 24 shares in the last quarter. 91.85% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director David A. Jr/Ky Jones sold 4,800 shares of the business’s stock in a transaction that occurred on Thursday, September 16th. The stock was sold at an average price of $401.00, for a total transaction of $1,924,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.40% of the company’s stock.

NYSE:HUM opened at $420.69 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.71 and a quick ratio of 1.71. Humana Inc. has a 1 year low of $370.22 and a 1 year high of $475.44. The stock’s 50 day simple moving average is $406.80 and its two-hundred day simple moving average is $428.72. The company has a market cap of $54.06 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.42 and a beta of 0.89.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 28th. The insurance provider reported $6.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $6.86 by $0.03. Humana had a return on equity of 13.62% and a net margin of 3.09%. The business had revenue of $20.65 billion for the quarter, compared to the consensus estimate of $20.51 billion. As a group, analysts anticipate that Humana Inc. will post 21.49 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 29th. Stockholders of record on Thursday, September 30th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Wednesday, September 29th. Humana’s dividend payout ratio is currently 14.93%.

A number of research firms have recently weighed in on HUM. Cowen began coverage on Humana in a research report on Thursday, September 9th. They set an “outperform” rating and a $479.00 price objective on the stock. SVB Leerink started coverage on Humana in a research report on Monday, September 27th. They set an “outperform” rating and a $494.00 price objective on the stock. Barclays started coverage on Humana in a research note on Thursday, September 9th. They set an “overweight” rating and a $500.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Humana from $440.00 to $514.00 and gave the company an “overweight” rating in a research note on Friday, July 9th. Finally, Morgan Stanley lifted their target price on Humana from $500.00 to $513.00 and gave the company an “overweight” rating in a research note on Tuesday, August 31st. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $486.92.

Humana Profile

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

Read More: Put Option

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.